Amyris Inc (AMRS) Receives $7.67 Average Price Target from Brokerages

Shares of Amyris Inc (NASDAQ:AMRS) have received an average recommendation of “Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.50.

AMRS has been the subject of a number of analyst reports. BidaskClub downgraded shares of Amyris from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Amyris in a research note on Tuesday, August 7th. Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. Finally, B. Riley set a $10.00 target price on shares of Amyris and gave the company a “buy” rating in a research note on Wednesday, October 3rd.

In other Amyris news, CFO Kathleen Valiasek bought 23,000 shares of the firm’s stock in a transaction on Tuesday, November 27th. The stock was acquired at an average price of $4.37 per share, with a total value of $100,510.00. Following the completion of the purchase, the chief financial officer now owns 251,630 shares of the company’s stock, valued at $1,099,623.10. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eduardo Alvarez bought 11,877 shares of the firm’s stock in a transaction on Wednesday, September 5th. The shares were acquired at an average cost of $8.45 per share, with a total value of $100,360.65. Following the purchase, the chief operating officer now directly owns 331,877 shares of the company’s stock, valued at approximately $2,804,360.65. The disclosure for this purchase can be found here. 21.80% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. B. Riley Financial Inc. grew its holdings in shares of Amyris by 364.2% during the third quarter. B. Riley Financial Inc. now owns 367,756 shares of the biotechnology company’s stock valued at $2,920,000 after buying an additional 288,537 shares during the last quarter. B. Riley Wealth Management Inc. purchased a new stake in shares of Amyris during the third quarter valued at approximately $159,000. Teachers Advisors LLC grew its holdings in shares of Amyris by 105.7% during the third quarter. Teachers Advisors LLC now owns 65,812 shares of the biotechnology company’s stock valued at $523,000 after buying an additional 33,813 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Amyris by 135.5% during the third quarter. AQR Capital Management LLC now owns 43,074 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 24,783 shares during the last quarter. Finally, Manatuck Hill Partners LLC purchased a new stake in shares of Amyris during the third quarter valued at approximately $944,000. Hedge funds and other institutional investors own 28.87% of the company’s stock.

AMRS stock opened at $4.94 on Wednesday. Amyris has a 1 year low of $3.11 and a 1 year high of $9.28. The stock has a market capitalization of $345.89 million, a P/E ratio of -1.62 and a beta of 0.27.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. During the same period in the prior year, the firm posted ($0.81) earnings per share. Amyris’s quarterly revenue was down 38.4% compared to the same quarter last year. On average, analysts anticipate that Amyris will post -1.34 EPS for the current year.

About Amyris

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit